Circadian Effects of Escitalopram
Depression

About this trial
This is an interventional basic science trial for Depression
Eligibility Criteria
Inclusion Criteria:
- 18-65 years old
- able to comply with requirements of the experimental protocol
- competent to sign informed consent
- have mild to severe major depressive disorder without psychotic features and without a seasonal pattern
- currently be under the care of a licensed mental health care provider or primary care physician
- Score > 7 when interviewed by a trained rater using the 21-Item Hamilton Depression Scale (HAM-D)
- be in good physical health
- not be suicidal
- not be taking any other antidepressant medications besides escitalopram during the study
- be free of antidepressant medications for 2-4 weeks prior to beginning the study
- not have a history of transmeridian travel or shift work in the past 2 months and have no plans for transmeridian travel or shift work for the duration of the study
- be able to maintain a regular sleep wake schedule for the weeks one and nine of study
- women of childbearing potential must have a negative pregnancy test and practice an acceptable method of birth control
Exclusion Criteria:
- abnormal heart, liver, or kidney function
- significant laboratory abnormalities on Complete Blood Count, Complete Metabolic Set, Thyroid Stimulating Hormone, EKG, & urinalysis
- shift work or transmeridian travel in the last 2 months
- current use of melatonin
- evidence of a primary sleep disorder by history
- women who are pregnant or lactating
- be taking medications with known sedative or stimulating effects or that would interfere with the production of melatonin
Sites / Locations
- Oregon Health & Science University
Arms of the Study
Arm 1
Experimental
Study Drug
Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.